product pipeline / R&D affecting expense
“As of March 31, 2026, we had an accumulated deficit of $343.0 million, primarily as a result of research and development and general and administrative expenses.”
TRVI 10-Q
Confirmed
Clinical Biotechnology
18 names are moving together; 83% are participating in the current session.
2 observed Confirmed episodes
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | Healthcare | -3.0% | Group member |
| VRDN | Viridian Therapeutics, Inc. | Healthcare | -3.9% | Group member |
| XNCR | Xencor, Inc. | Healthcare | -5.7% | 2/11 observed active sessions |
| NKTR | Nektar Therapeutics | Healthcare | -3.0% | 3/11 observed active sessions |
| RCUS | Arcus Biosciences, Inc. | Healthcare | -2.9% | 1/11 observed active sessions |
| CMPX | Compass Therapeutics, Inc. | Healthcare | -2.4% | Group member |
| PGEN | Precigen, Inc. | Healthcare | -2.6% | Group member |
| TRVI | Trevi Therapeutics, Inc. | Healthcare | -7.4% | 3/11 observed active sessions |
| ANAB | AnaptysBio, Inc. | Healthcare | +5.1% | 3/11 observed active sessions |
| PVLA | Palvella Therapeutics, Inc. | Healthcare | +0.8% | 3/11 observed active sessions |
| RLAY | Relay Therapeutics, Inc. | Healthcare | -6.4% | Group member |
| DFTX | Definium Therapeutics, Inc. | Healthcare | -7.3% | Group member |
| CGON | CG Oncology, Inc. | Healthcare | -3.8% | 1/11 observed active sessions |
| EWTX | Edgewise Therapeutics, Inc. | Healthcare | -9.2% | 1/11 observed active sessions |
| ALMS | Alumis Inc. | Healthcare | -0.9% | 3/11 observed active sessions |
| BCRX | BioCryst Pharmaceuticals, Inc. | Healthcare | -5.1% | 1/11 observed active sessions |
| RIGL | Rigel Pharmaceuticals, Inc. | Healthcare | -2.9% | 2/11 observed active sessions |
| AURA | Aura Biosciences, Inc. | Healthcare | +2.3% | 4/11 observed active sessions |
Why we believe this
Cohort
18 namesParticipation
83% this sessionObserved history
14 daily buildsFiling coverage
18/18 memberscredit / rates affecting interest expense
“Net cash used in operating activities during the three months ended March 31, 2025 was $10.7 million, primarily due to our net loss of $39.3 million, adjusted for addbacks for non-cash expenses of $26.2 million, which includes stock-based compensation, amortization of operating ROU assets, non-cash interest expense, income from marketable securities and net increases in working capital of $2.4 million.”
ANAB 10-Q
restructuring affecting expense
“The increased personnel related expenses and stock-based compensation were primarily due to severance costs along with increased headcount.”
TRVI 10-K
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
AMGN
RIGLpartner · Moving with the group now · 115 min observed
Filing receipt · AMGN / RIGL
“Other products in the US that are approved by the FDA to increase platelet production through binding to TPO receptors on megakaryocyte precursors include PROMACTA ® (No…”
RIGL · partner
PFE
EWTXsupplier · Not moving with the group now
Filing receipt · PFE / EWTX
“For oHCM patients who remain symptomatic, a sodium channel blocker with negative ionotropic drug properties may also be added, typically disopyramide (either Pfizer’s No…”
EWTX · supplier
MRK
NKTRpartner · Moving with the group now · 115 min observed
Filing receipt · MRK / NKTR
“Our development expense for NKTR-255 for the periods presented include our oncology clinical collaboration with Merck KGaA to evaluate the maintenance regimen of NKTR-25…”
NKTR · partner
ZBIO
VRDNpartner · Not moving with the group now
Filing receipt · ZBIO / VRDN
“In May 2022, we entered into a manufacturing development and supply agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical…”
VRDN · partner
GILD
RCUSpartner · Moving with the group now · 115 min observed
Filing receipt · GILD / RCUS
“TIGIT Program (domvanalimab) • In December 2025, we announced the discontinuation of the Phase 3 STAR-221 study, conducted in partnership with Gilead and Taiho, evaluati…”
RCUS · partner
History
2026-06-26 → 2026-07-1310 observed active sessions · 0% of active names held across the episode
2026-06-171 observed active session · 100% of active names held across the episode